The provisions of Sections  (Definitions) (to the extent applicable to surviving provisions), 4.5 (Preclinical Data), 4.6.1 (Clinical Trial Data), 8.12.4, 11 (Financial  Provisions) (limited to amounts due to a Party as of the expiration or termination of this Agreement, including as provided for under 17.2.2(vi) and 20.6(vi), and any associated obligations, e.g., reporting),   12.1 (Records), 12.2 (Audits), 13.1 (Ownership), Section 14 (Confidentiality), 15.2 (Disclosures Regarding the Agreement), 15.8 (Use of Name), 16 (Representations), 17.4 (Trading in Securities), Section 18 (Indemnification, Liability, Insurance), 20.3 (Effect of Expiration or Termination of Agreement), 20.4 (Additional Effects of Expiration), 20.5 (Additional Effects of Termination by Bayer Pursuant to Sections 20.2.1,  20.2.2, 20.2.3 or 20.2.4 or by Loxo Pursuant to Section 20.2.3 or 20.2.4), 20.7 (Bayer’s Additional Rights upon Loxo’s Insolvency), Section 22 (Dispute Resolution) and Section 23 (General Provisions) shall survive any expiration or termination of this Agreement. For clarity, a Party’s obligation to indemnity the other Party pursuant to Section 18 shall survive termination of this Agreement due to a material breach by the Party being indemnified.